Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | PLG | P00747 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509504 | 0.89 | BRAF (0.47) | CARM1HDAC6TLR9TLR8TLR7 | |
| SCHEMBL4963489 | 0.85 | CARM1 (0.49) | CARM1HDAC6CDK4CCNA2CCND1 | |
| SCHEMBL4964915 | 0.84 | RAB9A (0.48) | CARM1HDAC6 | |
| SCHEMBL4964897 | 0.82 | CARM1 (0.51) | CARM1HDAC6CDK4CCNA2CCND1 | |
| SCHEMBL12833480 | 0.82 | TLR9 (0.45) | CARM1HDAC6TLR9TLR8TLR7 | |
| SCHEMBL4963154 | 0.81 | HDAC6 (0.60) | CARM1HDAC6PDE10AF2F10 | |
| SCHEMBL4964947 | 0.81 | GSK3B (0.51) | CARM1HDAC6F2F10PRSS1 | |
| SCHEMBL4963532 | 0.81 | HDAC6 (0.50) | CARM1HDAC6PDE2APDE10AF2 | |
| SCHEMBL4965539 | 0.80 | HDAC6 (0.61) | CARM1HDAC6PDE10ACDK4CCNA2 | |
| SCHEMBL14090479 | 0.80 | CARM1 (0.46) | CARM1HDAC6PDE3BPDE3ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CARM1 785/4885HDAC6 541/4885TLR9 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.